126 related articles for article (PubMed ID: 34994590)
1. Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment.
Popat S; Sharma B; MacMahon S; Nicholson AG; Sharma RK; Schuster K; Lang Lazdunski L; Fennell D
JCO Precis Oncol; 2021 Nov; 5():39-43. PubMed ID: 34994590
[No Abstract] [Full Text] [Related]
2. Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib.
Cabezas-Camarero S; García-Barberán V; Pérez-Alfayate R; Gómez Del Pulgar ME; Cabrera-Martin MN; Casado-Fariñas I; Pérez-Segura P
Oncologist; 2024 May; 29(5):377-383. PubMed ID: 38438322
[TBL] [Abstract][Full Text] [Related]
3. Conversion surgery for locally advanced malignant pleural mesothelioma.
Terada Y; Isaka M; Murakami H; Kawata T; Konno H; Kojima H; Mizuno T; Ohde Y
Gen Thorac Cardiovasc Surg; 2020 Dec; 68(12):1547-1550. PubMed ID: 32166578
[TBL] [Abstract][Full Text] [Related]
4. Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study.
Ikeda T; Takemoto S; Senju H; Gyotoku H; Taniguchi H; Shimada M; Dotsu Y; Umeyama Y; Tomono H; Kitazaki T; Fukuda M; Soda H; Yamaguchi H; Fukuda M; Mukae H
Thorac Cancer; 2020 Jul; 11(7):1972-1978. PubMed ID: 32462731
[TBL] [Abstract][Full Text] [Related]
5. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740
[No Abstract] [Full Text] [Related]
6. Drug hypersensitivity syndrome in a patient receiving vismodegib.
Lam T; Wolverton SE; Davis CL
J Am Acad Dermatol; 2014 Mar; 70(3):e65-6. PubMed ID: 24528922
[No Abstract] [Full Text] [Related]
7. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
Meerang M; Bérard K; Felley-Bosco E; Lauk O; Vrugt B; Boss A; Kenkel D; Broggini-Tenzer A; Stahel RA; Arni S; Weder W; Opitz I
Mol Cancer Ther; 2016 May; 15(5):1095-105. PubMed ID: 26839306
[TBL] [Abstract][Full Text] [Related]
8. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
[TBL] [Abstract][Full Text] [Related]
9. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
Papastefanou VP; René C
Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
[TBL] [Abstract][Full Text] [Related]
10. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment.
Chen R; Lee WC; Fujimoto J; Li J; Hu X; Mehran R; Rice D; Swisher SG; Sepesi B; Tran HT; Chow CW; Little LD; Gumbs C; Haymaker C; Heymach JV; Wistuba II; Lee JJ; Futreal PA; Zhang J; Reuben A; Tsao AS; Zhang J
Clin Cancer Res; 2020 Oct; 26(20):5477-5486. PubMed ID: 32816946
[TBL] [Abstract][Full Text] [Related]
11. Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.
Doi H; Kuribayashi K; Kitajima K; Yamakado K; Kijima T
Clin Lung Cancer; 2020 Jan; 21(1):66-74.e2. PubMed ID: 31551134
[TBL] [Abstract][Full Text] [Related]
12. Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.
Ighilahriz M; Benfodda M; Sharpe H; Soufir N; Mourah S; Dumaz N; Battistella M; Savina A; Bouquet F; Nikolaev S; Basset-Seguin N
J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e422-e424. PubMed ID: 31187903
[No Abstract] [Full Text] [Related]
13. Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma.
Ferdinandus J; Barbato F; Chodyla M; Fendler WP; Kessler L; Pomykala KL; Metzenmacher M; Krefting F; Hager T; Umutlu L; Herrmann K; Christoph DC
J Nucl Med; 2021 Feb; 62(2):191-194. PubMed ID: 32532926
[TBL] [Abstract][Full Text] [Related]
14. Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.
Lendvai N; Yee AJ; Tsakos I; Alexander A; Devlin SM; Hassoun H; Korde N; Lesokhin AM; Landau H; Mailankody S; Koehne G; Chung DJ; Landgren O; Raje NS; Giralt S
Blood; 2016 May; 127(19):2355-6. PubMed ID: 27020089
[No Abstract] [Full Text] [Related]
15. Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient.
Koelblinger P; Dummer R; Laimer M; Hecht S; Bauer JW; Gaggl A; Kugler A
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e7-e8. PubMed ID: 28646606
[No Abstract] [Full Text] [Related]
16. Low-Dosage Apatinib as Rescuing Treatment in Advanced Malignant Pleural Mesothelioma.
Liu YY; Zhang WY; Zeng DX
Am J Ther; 2020; 27(3):e326-e327. PubMed ID: 32356954
[No Abstract] [Full Text] [Related]
17. [Not Available].
Basset-Seguin N
Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
[TBL] [Abstract][Full Text] [Related]
18. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib.
Lucero OM; Fitzmaurice S; Thompson C; Leitenberge J
Dermatol Online J; 2018 Feb; 24(2):. PubMed ID: 29630158
[TBL] [Abstract][Full Text] [Related]
19. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F
Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiotherapy for relapsed malignant pleural mesothelioma.
Spatola C; Militello C; Tocco A; Salamone V; Raffaele L; Migliore M; Pagana A; Milazzotto R; Chillura I; Pergolizzi S; Privitera G
Future Oncol; 2016 Dec; 12(23s):67-71. PubMed ID: 27651129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
